Drug Trial Radar · NCT06671405
An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions
Last checked: Nov 19, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Sep 25, 2024
Primary completion
Feb 17, 2025
Study completion Feb 17, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An open-label, fixed sequence study in healthy participants to assess the pharmacokinetics of AZD0780 when administered alone and in combination with itraconazole and carbamazepine, and to assess the pharmacokinetics of midazolam and ethinyl estradiol/levonorgestrel (EE and LNG) when administered alone and in combination with AZD0780.
Conditions
- Dyslipidaemia
Interventions
AZD0780Drug
Dose 1 and Dose 2
ItraconazoleDrug
* Period 2 (itraconazole administration only). * Period 3 (AZD0780 + itraconazole administration).
CarbamazepineDrug
* Period 2 (carbamazepine administration only). * Period 3 (AZD0780 + carbamazepine administration only).
MidazolamDrug
* Period 1 (midazolam administration only). * Period 3 (AZD0780 + midazolam administration).
Ethinyl estradiol/levonorgestrelDrug
* Period 1 (EE and LNG administration only). * Period 3 (AZD0780 + EE and LNG administration).
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUCinf (Area under concentration-time curve from time 0 to infinity)Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)
- AUClast (Area under concentration curve from time 0 to the last quantifiable concentration)Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)
- Cmax (Maximum observed drug concentration)Time frame: Period 1 (Day 1 to 11 Cohort 1 and Cohort 2) and Period 3 (Day 14-24 Part 1 and Day 27-37 Part 2)
- AUCinfTime frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)
- AUClastTime frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)
- CmaxTime frame: Period 1 (Day 1 to 2 Part 3 and Day 1 to 7 Part 4) and Period 3 (Day 11-12 Part 3 and Day 16 to 22 Part 4)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Brooklyn, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.